摘要
目的观察那格列奈和格列苯脲治疗后2型糖尿病患者血糖、糖化血红蛋白(HbA_(1c))及胰岛素浓度等指标的变化。方法71例2型糖尿病患者随机分为2组,那格列奈组口服那格列奈一日3次,每次120mg,格列苯脲组口服格列苯脲一日3次,每次2.5mg,均治疗4周。治疗后观察空腹血糖(FBG)、餐后2小时血糖(2hpBG)、HbA_(1c)、空腹胰岛素浓度(F-Ins)、餐后2小时胰岛素浓度(2hIns)、血压、甘油三酯(TG)和体重指数(BMI)等指标。结果那格列奈降糖效果与格列苯脲相似,但餐后胰岛素浓度未见升高,前者安全性优于后者。结论那格列奈用于2型糖尿病治疗疗效好,安全性高。
Objective Comparing the efficacy of nateglinide and glyburide for treating type 2 diabetes. Methods 71 cases of type 2 diabetes patients were randomly divided into two groups, the nateglinide group was treated by nateglinide, 120mg tid, the glyburide group was treated by glyburide 2.5mg tid. Both groups were treated for 4 weeks. Results The diabetic parameters in two groups were similar reduced, but the 2hIns in nateglinide group was lower than that in glyburide group. Conclusion Nateglinide is effective and well tolerated in type 2 diabetes.
出处
《世界临床药物》
CAS
2007年第11期689-691,共3页
World Clinical Drug
关键词
2型糖尿病
降血糖药
那格列奈
nateglinide
type 2 diabetes
antihyperglycemic agent
